Abstract
Background: Cyclosporine is a calcineurin inhibitor that is approved for short-term use to treat moderate to severe chronic plaque psoriasis. In Australia it is a requirement to have trialed and failed, or have a valid contraindication to, at least two of cyclosporine, methotrexate, acitretin, or nbUVB therapy to be eligible for subsidised biologic therapy for chronic plaque psoriasis in adults. Therefore, it is important in clinical practice throughout Australia that cyclosporine efficacy and safety is well understood.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
